1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015;65:87–108.
2.Gonzaga IM, Soareslima SC, de Santos PT, Blanco TC, de Reis BS. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer. 2012; 12: 569.
3.Fichter CD, Gudernatsch V, Przypadlo CM, Follo M, Schmidt G, Werner M, et al. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways. J Mol Med (Berl). 2014;92:1209–23.
4.Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. DIAGN PATHOL. 2013;8:76.
5.Zhan N, Dong W, Tang Y, Wang Z, Xiong C. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. MED ONCOL. 2012;29:933–40.
6.Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, et al. Frequencies of HER–2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:1253–60.
7.Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER–2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC CANCER. 2009;9:6.
8.Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:304–17.
9.Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J CLIN ONCOL. 2013;31:3997–4013.
10.Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, et al. HER–2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. DIS ESOPHAGUS. 2006;19:224–31.
11.NIG AMK, REEH M, DANCAU A, RATHJENS M, GROS S. Concordance of HER2 Status in Primary Tumour and Lymph Node Metastases in Patients with Esophageal Carcinoma. Anticancer Res. 2013; 33: 4975–82.
12.Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, et al. Targeting EGFR and HER–2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97:494–501.
13.Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, et al. Expression of Her–2 in carcinomas of the esophagus. AM J SURG PATHOL. 2010;34:1868–73.
14.Gibault L, Metges JP, Conan-Charlet V, Lozac’H P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93:107–15.
15.Hatogai K, Fujii S, Kojima T, Daiko H, Nomura S, Doi T, et al. Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017;143:2351–61.
16.Shibata-Kobayashi S, Yamashita H, Okuma K, Shiraishi K, Igaki H, Ohtomo K, et al. Correlation among 16 biological factors [p53, p21(waf1), MIB–1 (Ki–67), p16(INK4A), cyclin D1, E-cadherin, Bcl–2, TNF-alpha, NF-kappaB, TGF-beta, MMP–7, COX–2, EGFR, HER2/neu, ER, and HIF–1alpha] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma. ONCOL LETT. 2013;5:903–10.
17.Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, et al. c-erbB–2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2003;57:1323–7.
18.CHEN Y, ZHU S, XU X, ZHAO AN, HU J. Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinoma. 2016;11:745–52.
19.Fazlollahi L, Remotti HE, Iuga A, Yang HM, Lagana SM, Sepulveda AR. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens. ARCH PATHOL LAB MED. 2018;142:516–22.
20.Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:111–9.
21.Horii R, Matsuura M, Iwase T, Ito Y, Akiyama F. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer. BREAST CANCER-TOKYO. 2014;21:598–604.
22.Fusco N, Bosari S. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World J Gastroenterol. 2016;22:7926–37.
23.Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. ADV ANAT PATHOL. 2014;21:100–7.
24.Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018:O2018778738.
25.Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AR, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J CLIN ONCOL. 2017;35:446–64.
26.Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. LANCET. 2010;376:687–97.
27.Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. EUR J CANCER. 2014;50:1247–58.
28.Mimura K, Izawa S, Siba S, Maruyama T, Watanabe M, Kawaguchi Y, et al. [The effect of immune-based therapy with cytotoxic T lymphocyte and molecular targeting therapy for HER2 in esophageal squamous cell carcinoma]. Gan To Kagaku Ryoho. 2011;38:1918–20.
29.Zhang L, Ma J, Han Y, Liu J, Zhou W, Hong L, et al. Targeted therapy in esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016;10:595–604.